metformin
Semantic SEO entity — key topical authority signal for metformin in Google’s Knowledge Graph
Metformin is an oral biguanide antihyperglycemic medication and the guideline-recommended first-line therapy for type 2 diabetes mellitus. It reduces hepatic gluconeogenesis, improves peripheral insulin sensitivity and has a favorable safety and cost profile compared with many newer agents. Beyond glycemic control, metformin appears in care pathways for prediabetes, polycystic ovary syndrome (PCOS) and is investigated for weight and aging-related outcomes. For content strategy, metformin is a high-value anchor topic connecting pharmacology, clinical guidelines, nutrition for diabetes management, patient safety and access/cost content.
- Drug class
- Biguanide (oral antihyperglycemic)
- FDA approval (U.S.)
- 1994 (immediate-release metformin approved for type 2 diabetes)
- Typical starting dose
- 500 mg once or twice daily with meals (common titration to 1500–2000 mg/day)
- Maximum daily dose
- Immediate‑release: up to 2550 mg/day (ER formulations typically max 2000 mg/day)
- Renal guidance
- Reduce dose or use caution for eGFR 30–45 mL/min/1.73 m2; avoid if eGFR <30 mL/min/1.73 m2
- Common adverse effects
- Gastrointestinal (nausea, diarrhea) in ~10–30% of patients; lactic acidosis is rare (<10 per 100,000 patient‑years)
- Availability & cost
- Generic; retail US cash prices commonly available as low as $4–$20/month for typical generic regimens (varies by dose and pharmacy)
- Essential medicine status
- Listed on the WHO Model List of Essential Medicines
Clinical definition and primary indications
Indications include glycemic control in type 2 diabetes, use in some cases of prediabetes for delaying progression (when lifestyle interventions are insufficient), and metabolic management in PCOS where insulin resistance is implicated. Off-label or investigational uses include weight management adjuncts and studies into age-related metabolic effects; however, these uses require individualized clinical judgment.
Metformin's utility in care pathways stems from its combination of efficacy (average HbA1c reductions of ~1.0–1.5%), low risk of hypoglycemia when used alone, cardiovascular neutrality to modest benefit in some subgroups, low cost, and an overall favorable safety profile compared with many second-line agents.
Mechanism of action and pharmacology
Pharmacokinetically, metformin is absorbed from the small intestine, not metabolized by the liver, and is renally excreted unchanged. The plasma half-life is approximately 4–8 hours for immediate-release formulations; extended-release (ER) formulations provide smoother plasma concentrations and are associated with fewer gastrointestinal side effects in some patients.
Drug interactions are clinically relevant because renal clearance determines systemic exposure. Agents that reduce renal function or compete for renal tubular secretion (e.g., cimetidine, some antivirals) can increase metformin levels. Intravenous iodinated contrast and acute illness that impair renal perfusion are scenarios that require temporary discontinuation per many institutional protocols to minimize lactic acidosis risk.
Dosing, renal function, and safety monitoring
Renal function guides use: do not start if eGFR <45 mL/min/1.73 m2 is an increasingly conservative threshold for initiation in many guidelines; stop metformin if eGFR drops below 30 mL/min/1.73 m2. For patients with eGFR 30–45 mL/min/1.73 m2, dose reduction and increased monitoring are recommended. Assess renal function at baseline and at least annually (more frequently in older adults or with comorbid conditions).
Monitor for gastrointestinal tolerance, B12 deficiency (long-term use associated with decreased B12 absorption; check levels if anemia or neuropathy), and signs of rare but serious lactic acidosis (symptoms: malaise, myalgias, respiratory distress, somnolence). Educate patients to hold metformin around procedures involving iodinated contrast or with acute illnesses that can cause hypovolemia or renal impairment.
Nutrition, diet interactions, and role in diabetes management
Metformin does not replace the need for medical nutrition therapy (MNT) in diabetes; instead, it complements dietary strategies (carbohydrate counting, low-glycemic-index foods, portion control) to achieve glycemic targets and weight goals. In overweight patients, metformin may modestly support weight stabilization or modest weight loss when combined with calorie-controlled diets and physical activity.
Content linking metformin to nutrition can cover meal timing to reduce side effects, how different diets (low-carb, Mediterranean, plant-based) affect metformin efficacy and tolerability, and practical care plans that integrate medication use with dietary interventions and monitoring of glucose responses.
Comparative landscape: metformin vs other glucose-lowering agents
Compared with insulin, metformin does not typically cause hypoglycemia and is preferred as initial therapy when beta-cell function remains adequate. When combination therapy is required, metformin is usually continued for its beneficial metabolic profile and neutral-to-beneficial weight effects. In patients with cardiovascular disease or chronic kidney disease, guideline-directed selection of add-on agents (SGLT2 inhibitors or GLP-1 RAs) may supersede older agents for outcome benefits.
For content strategy, comparisons should highlight efficacy (HbA1c reduction), safety (hypoglycemia, weight, renal effects), cost/access, and guideline positioning to help clinicians and patients make informed therapy choices.
Regulatory status, access, cost, and off-label considerations
Regulators in many countries include boxed warnings or guidelines about lactic acidosis risk, renal function thresholds and contrast media management. Institutional protocols often specify holding metformin in the peri-procedural period when renal function may be temporarily impaired.
Off-label uses such as treatment of PCOS are common in practice, while investigational uses (longevity, cancer adjuncts) are subjects of active research; content addressing these areas should distinguish established indications from experimental evidence and reference randomized trials or guideline positions.
Content Opportunities
Frequently Asked Questions
What is metformin used for?
Metformin is used primarily to treat type 2 diabetes by lowering fasting and overall blood glucose; it is also used for prediabetes in some patients and for metabolic management in PCOS under clinician supervision.
How does metformin lower blood sugar?
Metformin reduces hepatic glucose production (gluconeogenesis), increases insulin sensitivity in peripheral tissues, and has effects on intestinal glucose handling; AMPK activation and mitochondrial effects are implicated in its mechanism.
What are common side effects of metformin?
The most frequent side effects are gastrointestinal—nausea, diarrhea, abdominal discomfort—especially during initiation. Long-term use can be associated with decreased vitamin B12 absorption; lactic acidosis is very rare but serious.
Is metformin safe with reduced kidney function?
Metformin should be used with caution when eGFR is 30–45 mL/min/1.73 m2 (dose reduction and monitoring advised) and is contraindicated if eGFR is <30 mL/min/1.73 m2 due to increased accumulation and lactic acidosis risk.
Can metformin cause weight loss?
Metformin is associated with modest weight loss or weight neutrality for many patients; it is not primarily a weight-loss drug but can support weight management when combined with diet and exercise.
Should I take metformin with food?
Yes—taking metformin with meals helps reduce gastrointestinal side effects and improves tolerability; extended-release formulations may further decrease GI symptoms for sensitive patients.
Can I drink alcohol while on metformin?
Excessive alcohol increases the risk of lactic acidosis in people taking metformin; moderate alcohol intake should be discussed with a clinician, and heavy or binge drinking should be avoided.
Do I need to stop metformin before undergoing contrast imaging?
Many institutions recommend holding metformin at the time of iodinated contrast administration for patients with borderline renal function and reassessing renal function before restarting, to reduce the small risk of contrast-associated metformin accumulation.
Topical Authority Signal
Thorough coverage of metformin signals topical authority across diabetes pharmacotherapy, safety, nutrition integration and access. High-quality, guideline‑aligned content on metformin unlocks authority for related topics—treatment pathways, medication comparisons, diet interactions and patient education—improving relevance for clinical and consumer search intents.